Goodwin Procter attorneys recently advised AMAG Pharmaceuticals on three simultaneous fundraising efforts in connection with the completion of its $700 million acquisition of Cord Blood Registry (CBR). The three financings included a $230.9 million public offering of common stock, a $350 million term loan and an offering of $500 million of senior notes due 2023.
As a high-growth specialty pharmaceuticals company, AMAG Pharmaceuticals brings therapeutics to market that provide clear benefits and improve people's lives. Based in Waltham, Mass., AMAG has a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care. AMAG continues to work to expand the impact of these and future products for patients by delivering on its aggressive growth strategy, which includes organic growth, as well as the pursuit of products and companies that align with AMAG's existing therapeutic areas or those that could benefit from its proven core competencies.
The Goodwin team advising AMAG on its common stock offering was led by partner Ettore Santucci and associates William Collins, Erin Svokos and Robert Dzialo. Goodwin partner Jennifer Bralower and associate Peter Hart led the team advising on the term loan. Partner James Barri and associates William Collins and Rob Dzialo led the Goodwin team advising on the senior notes.
The team advising on AMAG’s acquisition of CBR was led by partner Stuart Cable, counsel Joe Bernardi and associate Jacqueline Mercier.
Additional information regarding the three financings, as well as the completed CBR acquisition, is available in the AMAG Pharmaceuticals press release.